Table 3.
Medication and Clinical Outcome of EOSD and AOSD.
| EOSD n=25 |
AOSD n=166 [Ref. 44] |
|||
|---|---|---|---|---|
| Japanese patients, n (%) | 17 (68) | 166 (100) | ||
| Medication | ||||
| Glucocorticoid, n (%) | 23 (92) | 160 (96.4) | ||
| Pulse glucocorticoid therapy, n (%) | 7 (28) | 52 (31.3) | ||
| NSAIDs, n (%) | 9 (36) | 73 (44.0) | ||
| Immunosuppressants, n (%) | 6 (24) | 134 (80.7) | ||
| Biologics, n (%) | 2 (8) | 33 (19.9) | ||
| IVIG, n (%) | 2 (8) | - | ||
| Others, n (%) | - | 8 (4.8) | ||
| Clinical outcome | ||||
| Remission, n (%) | 23 (92) | 145/164 (88.4) | ||
| Flare, n (%) | 11 (44) | 66/169 (39.1) | ||
| AOSD-related death, n (%) | 0 (0) | 0 (0) | ||
| Follow up time, months | 23.7 | 58.8 |
EOSD: elderly-onset Still’s disease, AOSD: adult-onset Still’s disease, NSAIDs: non-steroidal anti-inflammatory drugs, IVIG: intravenous immunoglobulin